{"disease":{"id":"histiocytosis","name":"histiocytosis"},"drugs":{"marketed":[{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"vinblastin","indication_name":"Langerhans cell histiocytosis, disseminated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"emapalumab-lzsg","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Emapalumab-Lzsg","company_name":"Swedish Orphan Biovitrum","drug_phase":"discontinued","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted."},{"drug_id":"emapalumab","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gamifant","generic_name":"EMAPALUMAB","company_name":"Novimmune S.A.","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":55,"revenue":null,"mechanism":"Gamifant works by blocking the action of interferon gamma, a protein that helps coordinate the immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04100408","title":"Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":647,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06197204","title":"Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell Histiocytosis","phase":"","overall_status":"RECRUITING","enrollment_count":570,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07157683","title":"Biomarkers in Systemic Histiocytosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03827343","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04665674","title":"Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06339177","title":"Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04773366","title":"A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT04077905","title":"Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04943211","title":"Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Anna Raciborska","has_results":false},{"nct_id":"NCT05841342","title":"Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07431060","title":"Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT06078969","title":"Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT03510650","title":"Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT05803629","title":"Characterizing Histiocytosis With 68Ga-FAPI PET/CT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03742115","title":"Etoposide in the First-line Treatment of Adult EBV-HLH","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04120090","title":"Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07488728","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT07371182","title":"Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions","phase":"NA","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT02069899","title":"A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT05997602","title":"To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT02668120","title":"Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic","phase":"","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT07187193","title":"Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03795909","title":"Ruxolitinib Combined With Dexamethasone for HLH","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Capital Research Institute of Pediatrics","has_results":false},{"nct_id":"NCT05315336","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05828069","title":"A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04121819","title":"AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07204041","title":"Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03259230","title":"Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT03312751","title":"Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT05001737","title":"Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT06573671","title":"Histiocytosis in Injecting Drug Users","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT07208058","title":"A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT05384743","title":"Rituximab Monotherapy for EBV-HLH and CAEBV","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06951971","title":"Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02472054","title":"Treatment of Familiar Lymphohistiocytosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07369739","title":"Golidocitinib Combined With Selinexor for CAEBVD","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07339345","title":"Prospective Single-Arm Clinical Trial of GO Regimen for HLH.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07525466","title":"Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT04943198","title":"Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Anna Raciborska","has_results":false},{"nct_id":"NCT05092815","title":"The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05775705","title":"L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03526250","title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07531069","title":"Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04120519","title":"Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03213665","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03698994","title":"Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}